Beike Biotech
  • Home
  • Beike History
  • Research & Development
    • Technology
    • Pipeline
  • Quality
  • Partnerships
  • News & Updates
  • Contact
Beike Biotech Pipeline

Pipeline

Timmune

In 2015, Beike founded Timmune to develop what now comprises of cell therapies and fusion protein molecule drugs based on proprietary MAR and TriTE technology.

ALT-803

In 2014, Beike Biotechnology signed an exclusive China licensing agreement with Altor Bioscience to develop and commercialize ALT-803 in China.

Product Discovery IND Enabling Phase 1 Phase 2 Phase 3 BLA In cooperation with
CAR-T/CD19 with TriTE construct
MAR-T/GP100 with TriTE construct
MAR-T/WT1 with TriTE construct
MAR-T/ESO1 with TriTE construct
MAR-TriTE/CD19
MAR-TriTE/WT1
MAR-TriTE/ESO1
ALT-803 | NMI Bladder Cancer

Connect With Us

facebook  youtube  twitter   vimeo  linkedin  google-plus

Menu

  • Home
  • Technologies
  • Pipeline
  • Quality
  • Partnership
  • News & Updates
  • Contact

Our Partners

  • Beike Cell Therapy
  • Better Being Hospital

© 2021 Beike Biotechnology Co., Ltd.
All rights reserved.